Core Viewpoint - Haisheng Pharmaceutical (002099.SZ) has received approval from the National Medical Products Administration for the marketing application of Diquafosol Sodium, a P2Y2 receptor agonist used in eye drop formulation for the treatment of dry eye disease [1] Group 1 - Diquafosol Sodium acts on the P2Y2 receptors located on the conjunctival epithelium and goblet cell membranes [1] - The mechanism of Diquafosol Sodium involves upregulating intracellular calcium ion concentration, which promotes the secretion of water and mucin, thereby improving symptoms of dry eye [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the marketing application of Diquafosol Sodium, a P2Y2 receptor agonist used in eye drops for the treatment of dry eye disease [1] Group 1: Company Information - The approved product, Diquafosol Sodium, is specifically formulated as an eye drop solution [1] - The company anticipates that the sales revenue for Diquafosol Sodium eye drops in urban public hospitals in China will reach RMB 131 million in 2024 [1] Group 2: Industry Context - Diquafosol Sodium is positioned within the therapeutic area of dry eye disease, which is a significant market in ophthalmology [1]

Core Viewpoint - The approval of the sodium diquafosol raw material drug by the National Medical Products Administration enhances the company's product pipeline and competitiveness, although it will not have a significant short-term impact on performance due to pending GMP inspections and various uncertainties regarding production and sales timing [1] Group 1 - The company has received the approval notice for the sodium diquafosol raw material drug, which is packaged in 5kg barrels and meets drug registration requirements [1] - Sodium diquafosol is a P2Y2 receptor agonist, and its eye drops are used for the treatment of dry eye syndrome, with projected sales of 130.89 million yuan in public hospitals in Chinese cities in 2024 [1] - The approval will enrich the company's product pipeline and enhance its competitiveness in the market [1] Group 2 - The company still needs to pass GMP inspections, which introduces uncertainty regarding the short-term impact on performance [1] - The timing and conditions of production and sales are influenced by multiple factors, leading to further uncertainties [1]